Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine
This article was originally published in The Pink Sheet Daily
Executive Summary
As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.
You may also be interested in...
PhRMA, Others Look For Savings In Reduced Drug Interactions
Reducing the instances of adverse events related to drug-drug interactions is among the options to reduce health care spending presented by both the Pharmaceutical Research and Manufacturers of America and the American Medical Association
PhRMA, Others Look For Savings In Reduced Drug Interactions
Reducing the instances of adverse events related to drug-drug interactions is among the options to reduce health care spending presented by both the Pharmaceutical Research and Manufacturers of America and the American Medical Association
Cost-Cutting Sequel Yields Little Surprise: PhRMA Supports Efficient Medication Use, More Drug Development, Expanded Access
Following up on their pledge to help reduce growing health costs, PhRMA, other health groups provide more specifics to President Obama.